Martin Goldfarb, O.C., Joins Covalon’s Board of Directors
April 23 2020 - 6:30AM
Business Wire
Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV:
COV; OTCQX: CVALF), an advanced medical technologies company, is
delighted to announce that Mr. Martin Goldfarb has joined its Board
of Directors.
Brian Pedlar, Covalon’s CEO, said, “I am delighted that we have
been able to attract an individual as accomplished and experienced
as Martin Goldfarb to join Covalon’s Board. Martin has been a
significant long-time Covalon shareholder and I look forward to
benefiting further from his unique insights and experiences.”
Martin Goldfarb said, “I have been an enthusiastic Covalon
investor for almost 10 years. I love that Covalon successfully
innovates in the healthcare arena – saving lives by developing new
medical technologies. I look forward to contributing to Covalon’s
further progress. I sincerely believe there is much more that can
be achieved by Covalon for patients, healthcare providers and
shareholders alike.”
Mr. Goldfarb is well-recognized as a successful entrepreneur and
a leading expert in the study of human behavior as it relates to
the marketplace and society. As an officer, director, and investor
in both public and private companies, Mr. Goldfarb has been
instrumental in brand and strategic development, management
mentoring and the creation of value, ultimately leading to
substantial return on investment.
He is Chairman of Almada Inc., President of Goldfarb Ventures,
private equity companies and Principal at Goldfarb Intelligence
Marketing.
In 1966, Mr. Goldfarb established Goldfarb Consultants, a market
research consulting firm. Over the next thirty years, he proceeded
to grow the company and to establish Goldfarb Consultants as a
leader in the field of market research. Starting in Toronto, he
built Goldfarb Consultants into an international company with 26
worldwide offices. Mr. Goldfarb sold Goldfarb Consultants in
1998.
Mr. Goldfarb has consulted to a number of national and
international organizations. He also served as official pollster to
the Liberal Party of Canada from 1973 to 1992. He was formerly
Co-Chair of Kantar (WPP’s market research division).
Mr. Goldfarb is Chairman, President and CEO of The Goldfarb
Corporation, a TSX and then a NEX Board of the TSX Venture Exchange
company, until it became a private corporation in 2011. He is a
director of NoNO Inc., a pharmaceutical research company.
He was also Director and Chairman of Dayforce, a workforce
performance software company until its sale. He was Chairman and
Director of SMK Speedy International Inc (publicly listed) until
its sale in 2004. Under Mr. Goldfarb’s guidance, Speedy Muffler
King became a strong and successful brand in France, Belgium and
Germany. He was Director, investor, and non-executive Chair of
Jempak until its sale. Mr. Goldfarb is former Director and Chairman
of Workbrain and former Director of Altamira and Noma Industries
Limited. He was a founder of Fast Company magazine.
Mr. Goldfarb co-authored “Marching to a Different Drummer” in
1988 and “Affinity: Beyond Branding“ in 2010.
Mr. Goldfarb has a B.A. in Anthropology and an M.A. in Sociology
from the University of Toronto. In 2009 Mr. Goldfarb was awarded an
Honorary Doctorate of Laws from York University. He is an inaugural
recipient of the University College, University of Toronto,
Distinguished Alumni Award.
In 1998, Mr. Goldfarb was designated an Officer of the Order of
Canada in recognition of his pioneering work in the market research
industry and philanthropic activities.
Mr. Goldfarb sits on the Toronto General and Western Hospital
Foundation board and is a member of the hospital’s Peter Munk
Cardiac Centre Innovation Committee.
Mr. Goldfarb’s appointment to Covalon’s Board of Directors is
subject to TSX approval.
About Covalon
Covalon Technologies Ltd. researches, develops, and
commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products, and
services address the advanced healthcare needs of medical device
companies, healthcare providers, and individual consumers.
Covalon's technologies are used to prevent, detect, and manage
medical conditions in specialty areas such as infection control,
vascular access, surgical procedures, advanced wound care, and
medical device coatings. To learn more about Covalon, visit our
website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including completion of
integration of the AquaGuard acquisition, the difficulty in
predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200423005164/en/
Brian Pedlar, CEO, Covalon Technologies Ltd. Email:
bpedlar@covalon.com Phone: 905.568.8400 x 233 Toll free:
1.877.711.6055 Web site: www.covalon.com Twitter: @covalon
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Covalon Technologies (TSXV:COV)
Historical Stock Chart
From Apr 2023 to Apr 2024